Genmab Completes Accrual in HuMax-CD20(TM) Phase I/II CLL Study
"The team at Genmab has worked hard to ensure rapid recruitment in this study," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We look forward to seeing efficacy data from this study."
The first important milestone for this study, the safety of using HuMax-CD20 in these patients at the planned dose levels, seems to have been achieved since no side effects limiting the continued recruitment of patients were observed.
The total follow up period for this study is 12 months from treatment start and the primary endpoint of the trial is objective response over the period from screening to week 19.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.